KR20130043642A - B세포활성인자길항제 및 그의 제조방법과 용도 - Google Patents

B세포활성인자길항제 및 그의 제조방법과 용도 Download PDF

Info

Publication number
KR20130043642A
KR20130043642A KR1020127033484A KR20127033484A KR20130043642A KR 20130043642 A KR20130043642 A KR 20130043642A KR 1020127033484 A KR1020127033484 A KR 1020127033484A KR 20127033484 A KR20127033484 A KR 20127033484A KR 20130043642 A KR20130043642 A KR 20130043642A
Authority
KR
South Korea
Prior art keywords
sequence
protein
cell activator
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127033484A
Other languages
English (en)
Korean (ko)
Inventor
리 양
위추안 웨
Original Assignee
시추안 유니버시티
씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시추안 유니버시티, 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 filed Critical 시추안 유니버시티
Publication of KR20130043642A publication Critical patent/KR20130043642A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127033484A 2010-05-26 2011-05-26 B세포활성인자길항제 및 그의 제조방법과 용도 Ceased KR20130043642A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2010101839059A CN101851278B (zh) 2010-05-26 2010-05-26 B细胞激活因子拮抗剂及其制备方法与用途
CN201010183905.9 2011-05-26
PCT/CN2011/074687 WO2011147320A1 (zh) 2010-05-26 2011-05-26 B细胞激活因子拮抗剂及其制备方法与用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020167020322A Division KR101810551B1 (ko) 2010-05-26 2011-05-26 B세포 활성인자길항제 및 그의 제조방법과 용도

Publications (1)

Publication Number Publication Date
KR20130043642A true KR20130043642A (ko) 2013-04-30

Family

ID=42802979

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127033484A Ceased KR20130043642A (ko) 2010-05-26 2011-05-26 B세포활성인자길항제 및 그의 제조방법과 용도
KR1020167020322A Active KR101810551B1 (ko) 2010-05-26 2011-05-26 B세포 활성인자길항제 및 그의 제조방법과 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167020322A Active KR101810551B1 (ko) 2010-05-26 2011-05-26 B세포 활성인자길항제 및 그의 제조방법과 용도

Country Status (6)

Country Link
US (1) US9290582B2 (https=)
EP (1) EP2578603B1 (https=)
JP (2) JP2013529900A (https=)
KR (2) KR20130043642A (https=)
CN (1) CN101851278B (https=)
WO (1) WO2011147320A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101851278B (zh) * 2010-05-26 2013-03-13 石药集团中奇制药技术（石家庄）有限公司 B细胞激活因子拮抗剂及其制备方法与用途
CN106220740A (zh) * 2016-08-18 2016-12-14 中山大学 可溶性蛋白baff在b细胞体外培养及扩增的应用
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
ES2827148B2 (es) * 2019-11-19 2021-10-19 Instituto Nac De Investigacion Y Tecnologia Agraria Y Alimentaria Inia Plásmido codificante para el receptor del factor de activación de células B (BAFF-R) y usos del mismo en el tratamiento y prevención de enfermedades inflamatorias en peces
EP4146684A2 (en) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
AU2024239150A1 (en) 2023-03-21 2025-10-02 Biograph 55, Inc. Cd19/cd38 multispecific antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
BRPI0209933B8 (pt) * 2001-05-24 2021-05-25 Zymogenetics Inc proteína de fusão, e, molécula de ácido nucleico
BR0211614A (pt) 2001-08-03 2006-10-31 Genentech Inc polipeptìdeo tacis e br3 e empregos dos mesmos
JP2007526220A (ja) 2003-06-05 2007-09-13 ジェネンテック・インコーポレーテッド Ｂ細胞疾患の併用療法
SI2272868T1 (sl) 2003-06-05 2015-07-31 Genentech, Inc., Kombinirana terapija za B-celične motnje
CN101120021A (zh) 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
JP2010501622A (ja) 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ−融合タンパク質の精製法
CN101678106B (zh) * 2007-03-27 2013-06-05 津莫吉尼蒂克斯公司 用于治疗自身免疫疾病的BLyS抑制和/或APRIL抑制与免疫抑制剂的组合
CA2739608A1 (en) * 2008-10-07 2010-04-15 The Regents Of The University Of California Recombinant nell protein production
CN101851278B (zh) 2010-05-26 2013-03-13 石药集团中奇制药技术（石家庄）有限公司 B细胞激活因子拮抗剂及其制备方法与用途

Also Published As

Publication number Publication date
WO2011147320A1 (zh) 2011-12-01
KR101810551B1 (ko) 2017-12-19
JP2016019527A (ja) 2016-02-04
EP2578603B1 (en) 2018-11-14
US20130089549A1 (en) 2013-04-11
EP2578603A4 (en) 2014-03-26
EP2578603A1 (en) 2013-04-10
CN101851278A (zh) 2010-10-06
JP6320973B2 (ja) 2018-05-09
US9290582B2 (en) 2016-03-22
JP2013529900A (ja) 2013-07-25
KR20160102066A (ko) 2016-08-26
CN101851278B (zh) 2013-03-13

Similar Documents

Publication Publication Date Title
DK2298347T3 (en) COAGULATION FACTOR CHEMICAL PROTEINS FOR TREATING A HEMOSTATIC DISORDER
KR20060022262A (ko) Ｇｌｐ-1 유사체 융합 단백질
JP7268202B2 (ja) 代謝性疾患を治療するための融合タンパク質
KR101810551B1 (ko) B세포 활성인자길항제 및 그의 제조방법과 용도
KR102696275B1 (ko) 염증을 치료 및 예방하기 위한 조성물 및 방법
KR102440820B1 (ko) ApoA-1 융합 폴리펩티드 및 관련 조성물 및 방법
JPH03500122A (ja) 成長ホルモンレセプター
JP7843711B2 (ja) 多選択性タンパク質
KR20140036202A (ko) 조직 재생을 유도하기 위한 펩티드 및 그의 이용
CN112218884A (zh) 由白介素-2突变蛋白和i型干扰素构成的融合蛋白
KR20160048103A (ko) Vegf-c 및 ccbe1의 치료적 용도
JP2018535964A (ja) 線維芽細胞増殖因子（ｆｇｆ）１アナログによるステロイド誘導性高血糖の処置
JP2016520053A (ja) 腫瘍微小環境における血管再生の抑制及び適応免疫応答の活性化を有する二機能の融合タンパク質及びその遺伝子並びに使用
CA2838340A1 (en) Method of treating or ameliorating metabolic disorders using clec-2
MXPA06003695A (es) Usos terapeuticos de variantes de quimiocinas.
KR20160113268A (ko) 이기능 융합단백질,이의 제조방법 및 용도
JP2001509372A (ja) 血小板凝集に関与する細胞表面受容体であるヒトｆ１１抗原
US11248036B2 (en) Mutant tumor necrosis factor receptor superfamily (TNFsfR) ligands and methods of making and using same
CN102317320A (zh) 能够结合于VEGF-A和TNF-α的融合蛋白
CN108404119A (zh) Fgf-21类似物的制备及在血栓治疗中的应用
JPWO1999014325A1 (ja) 新規Ｆａｓリガンド誘導体
KR20230003219A (ko) Pd-1에 대한 향상된 친화도를 가진 pd-l1 변이체
KR101153394B1 (ko) 레서스 원숭이 ｐｄｌ-1 융합 이뮤노글로불린
CN102028935A (zh) 败血症以及败血症休克的预测、预防和治疗方法及试剂盒
RU2825102C2 (ru) Рекомбинантные белки с доменами ccn и слитые белки

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20121221

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140925

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150922

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160427

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150922

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20140925

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20160725